Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

April 30, 2012

Study Completion Date

February 28, 2015

Conditions
NeoplasmsBreast NeoplasmsBreast Cancer
Interventions
DRUG

AZD8931

Tablet Oral bid

DRUG

Paclitaxel

IV once weekly for 3 weeks followed by a week off (repeated cycles)

DRUG

Placebo

Oral bid (twice daily)

Trial Locations (38)

Unknown

Research Site, Brussels (Jette)

Research Site, Leuven

Research Site, Namur

Research Site, Sint-Niklaas

Research Site, São Paulo

Research Site, Sofia

Research Site, Stara Zagora

Research Site, Varna

Research Site, Vratsa

Research Site, Halifax

Research Site, London

Research Site, Ottawa

Research Site, Brno

Research Site, Jičín

Research Site, Olomouc

Research Site, Prague

Research Site, Praha 4 - Krc

Research Site, Znojmo

Research Site, Villejuif

Research Site, Budapest

Research Site, Debrecen

Research Site, Győr

Research Site, Szeged

Research Site, Lido di Camaiore

Research Site, Modena

Research Site, Treviglio

Research Site, Panama City

Research Site, Lima

Research Site, Barcelona

Research Site, Madrid

Research Site, Valencia

Research Site, Uppsala

Research Site, Chur

Research Site, Glasgow

Research Site, Leicester

Research Site, London

Research Site, Nottingham

Research Site, Surrey

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY